EN 简
About CARsgen®
We focus on innovative CAR T-cell therapies

We are biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases.

Read More
About CARsgen<sup>®</sup>
Pipeline
Pipeline
Innovative and differentiated product pipeline

We develop innovative CAR-T technologies to empower the next generation pipeline products.

Read More
We have built an integrated cell therapy platform
<p>THANK-uCAR<sup>®</sup></p>

THANK-uCAR®

Allogeneic CAR-T platform
<p>CycloCAR<sup>®</sup></p>

CycloCAR®

Cytokine and Chemokine Loaded CAR
<p>LADAR<sup>®</sup></p>

LADAR®

Local Action Driven by Artificial Receptor
News Center
2025-05-15
CARsgen’s CT071 Abstract Published on EHA Website
2025-05-12
CARsgen Announces Preliminary Clinical Data for Allogeneic BCMA CAR-T CT0596, Demonstrating Favorable Safety and Efficacy
2025-04-29
EHA Preview | CARsgen® to Present Results of CT071 at 2024 EHA Annual Congress
2025-03-31
CARsgen® Announces Abstract of Satri-cel Research Results Accepted for Oral Presentation at 2025 ASCO Annual Meeting
2025-03-19
CARsgen Announced 2024 Annual Results
2025-03-03
CARsgen’s Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA